Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radgocitabine - Delta-Fly Pharma

Drug Profile

Radgocitabine - Delta-Fly Pharma

Alternative Names: CNDAC; DFP-10917; NS 917; TAS-109

Latest Information Update: 13 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Delta-Fly Pharma
  • Developer Delta-Fly Pharma; Nippon Shinyaku
  • Class Amines; Antineoplastics; Nitriles; Pyrimidines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • No development reported Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 08 Mar 2024 Delta Fly Pharma had submitted the protocol to FDA of the phase I/II study of DFP 10917 combined with Venetoclax (VTX) in acute myeloid leukemia
  • 07 Jan 2024 Delta Fly Pharma has patent protection for combination therapy of radgocitabine and venetoclax in Acute myeloid leukaemia the US, Japan and Taiwan
  • 07 Jan 2024 Delta-Fly Pharma plans a phase I/II trial for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top